[1] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
|
[2] |
Chinese Society of Endocrinology, Chinese Medical Association. Guidelines for the diagnosis and treatment of thyroid disorders in China—Thyroiditis[J]. Natl Med J China, 2008, 47(9): 784-785. DOI: 10.3321/j.issn:0578-1426.2008.09.032.
中华医学会内分泌学分会. 中国甲状腺疾病诊治指南——甲状腺炎[J]. 中华内科杂志, 2008, 47(9): 784-785. DOI: 10.3321/j.issn:0578-1426.2008.09.032.
|
[3] |
ZHANG W, LI LM, XU D, et al. Recommendations of diagnosis and treatment of primary Sjögren's syndrome in China[J]. Natl Med J China, 2020, 59(4): 269-276. DOI: 10.3760/cma.j.cn112138-20200113-00021.
张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59(4): 269-276. DOI: 10.3760/cma.j.cn112138-20200113-00021.
|
[4] |
Chinese Society of Rheumatology, Chinese Lupus Treatment and Research Group, National Clinical Research Center for Skin and Immune Diseases. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus[J]. Natl Med J China, 2020, 59(3): 172-185. DOI: 10.3760/cma.j.issn.0578-1426.2020.03.002.
中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185. DOI: 10.3760/cma.j.issn.0578-1426.2020.03.002.
|
[5] |
LU JH. Chinese consensus on the diagnosis and treatment of polymyositis[J]. Chin J Neurol, 2015, 48(11): 946-949. DOI: 10.3760/cma.j.issn.1006-7876.2015.11.004.
卢家红. 中国多发性肌炎诊治共识[J]. 中华神经科杂志, 2015, 48(11): 946-949. DOI: 10.3760/cma.j.issn.1006-7876.2015.11.004.
|
[6] |
Chinese Society of Rheumatology. Guidelines for the diagnosis and treatment of antiphospholipid syndrome[J]. Chin J Rheumatol, 2011, 15(6): 407-410. DOI: 10.3760/cma.j.issn.1007-7480.2011.06.012.
中华医学会风湿病学分会. 抗磷脂综合征诊断和治疗指南[J]. 中华风湿病学杂志, 2011, 15(6): 407-410. DOI: 10.3760/cma.j.issn.1007-7480.2011.06.012.
|
[7] |
GOET JC, MURILLO PEREZ CF, HARMS MH, et al. A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis[J]. Am J Gastroenterol, 2021, 116(7): 1514-1522. DOI: 10.14309/ajg.0000000000001285.
|
[8] |
WANG LF, ZHANG K, YANG F, et al. Current status of diagnosis and treatment of primary biliary cholangitis and related challenges in China[J]. J Clin Hepatol, 2016, 32(10): 1833-1837. DOI: 10.3969/j.issn.1001-5256.2016.10.001.
王立峰, 张可, 杨帆, 等. 中国原发性胆汁性胆管炎的诊治现状和挑战[J]. 临床肝胆病杂志, 2016, 32(10): 1833-1837. DOI: 10.3969/j.issn.1001-5256.2016.10.001.
|
[9] |
FLOREANI A, FRANCESCHET I, CAZZAGON N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 192-197. DOI: 10.1007/s12016-014-8427-x.
|
[10] |
TU RF, YANG X, TANG YM. Research advances in primary biliary cholangitis with extrahepatic autoimmune diseases[J]. J Clin Hepatol, 2020, 36(6): 1398-1401. DOI: 10.3969/j.issn.1001-5256.2020.06.046.
涂荣芳, 杨雪, 唐映梅. 原发性胆汁性胆管炎合并肝外自身免疫性疾病的研究进展[J]. 临床肝胆病杂志, 2020, 36(6): 1398-1401. DOI: 10.3969/j.issn.1001-5256.2020.06.046.
|
[11] |
CROWE JP, CHRISTENSEN E, BUTLER J, et al. Primary biliary cirrhosis: The prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome[J]. Gastroenterology, 1980, 78(6): 1437-1441.
|
[12] |
GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42(5): 1194-1202. DOI: 10.1002/hep.20907.
|
[13] |
VINCKEN S, REYNAERT H, SCHIETTECATTE J, et al. Liver cirrhosis and thyroid function: Friend or foe?[J]. Acta Clin Belg, 2017, 72(2): 85-90. DOI: 10.1080/17843286.2016.1215641.
|
[14] |
SILVEIRA MG, MENDES FD, DIEHL NN, et al. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease[J]. Liver Int, 2009, 29(7): 1094-1100. DOI: 10.1111/j.1478-3231.2009.02003.x.
|
[15] |
ZHAO ZB, LIAN ZX. Immunological pathogenesis of primary biliary cholangitis[J]. J Clin Hepatol, 2017, 33(11): 2112-2116. DOI: 10.3969/j.issn.1001-5256.2017.11.012.
赵志斌, 廉哲雄. 原发性胆汁性胆管炎的免疫学发病机制[J]. 临床肝胆病杂志, 2017, 33(11): 2112-2116. DOI: 10.3969/j.issn.1001-5256.2017.11.012.
|
[16] |
JIN X, SHANG XM, CHEN HB, et al. Study on dynamic changes and significance of the peripheral blood regulatory T cells (Treg) and Th17 cells in patients with Hashimoto's thyroditis[J]. J Clin Exp Med, 2018, 17(19): 2092-2094. DOI: 10.3969/j.issn.1671-4695.2018.19.022.
金鑫, 尚雪梅, 陈海波, 等. 桥本甲状腺炎患者外周血调节性T细胞与Th17细胞的动态变化及其意义[J]. 临床和实验医学杂志, 2018, 17(19): 2092-2094. DOI: 10.3969/j.issn.1671-4695.2018.19.022.
|
[17] |
KUŚA, ARŁUKOWICZ-GRABOWSKA M, SZYMAŃSKI K, et al. Genetic risk factors for autoimmune thyroid disease might affect the susceptibility to and modulate the progression of primary biliary cholangitis[J]. J Gastrointestin Liver Dis, 2017, 26(3): 245-252. DOI: 10.15403/jgld.2014.1121.263.kus.
|
[18] |
MARTÍNEZ A, VARADÉ J, MÁRQUEZ A, et al. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases[J]. Arthritis Rheum, 2008, 58(9): 2598-2602. DOI: 10.1002/art.23792.
|
[19] |
CHALIFOUX SL, KONYN PG, CHOI G, et al. Extrahepatic manifestations of primary biliary cholangitis[J]. Gut Liver, 2017, 11(6): 771-780. DOI: 10.5009/gnl16365.
|
[20] |
SOROKIN A, BROWN JL, THOMPSON PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review[J]. Atherosclerosis, 2007, 194(2): 293-299. DOI: 10.1016/j.atherosclerosis.2006.11.036.
|
[21] |
LIU X, LIU YP, GAO XS, et al. Progress on dyslipidemia in primary biliary cholangitis[J/CD]. Chin J Hepatol (Electronic Version), 2020, 12(3): 17-22. DOI: 10.3969/j.issn.1674-7380.2020.03.004.
刘晓, 刘亚平, 高学松, 等. 原发性胆汁性胆管炎合并血脂异常研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(3): 17-22. DOI: 10.3969/j.issn.1674-7380.2020.03.004.
|
[22] |
ZÖLLER B, LI X, SUNDQUIST J, et al. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: A nationwide follow-up study from Sweden[J]. PLoS One, 2012, 7(3): e33442. DOI: 10.1371/journal.pone.0033442.
|
[23] |
UNGPRASERT P, WIJARNPREECHA K, AHUJA W, et al. Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies[J]. Hepatol Res, 2015, 45(11): 1055-1061. DOI: 10.1111/hepr.12452.
|
[24] |
FLOREANI A, CAZZAGON N, FRANCESCHET I, et al. Metabolic syndrome associated with primary biliary cirrhosis[J]. J Clin Gastroenterol, 2015, 49(1): 57-60. DOI: 10.1097/MCG.0000000000000029.
|
[25] |
FLOREANI A, MANGINI C, REIG A, et al. Thyroid dysfunction in primary biliary cholangitis: A comparative study at two european centers[J]. Am J Gastroenterol, 2017, 112(1): 114-119. DOI: 10.1038/ajg.2016.479.
|